KLI

Transcatheter Arterial Embolization for Palliation of Uterine Body Cancer Bleeding

Metadata Downloads
Abstract
Purpose: This study aimed to evaluate the efficacy and safety of transcatheter arterial embolization (TAE) for bleeding due to uterine body cancer.

Materials and methods: In this retrospective study, six patients with varying types of uterine body cancer who underwent TAE for bleeding control were investigated. Angiographic findings, cross-sectional images, TAE details, and clinical outcomes were studied. Technical and clinical success rates were calculated.

Results: The identified patients had endometrioid adenocarcinoma, sarcoma, and gestational trophoblastic neoplasia, and most were patients with advanced-stage cancer. In four patients, tumor bleeding presented as vaginal bleeding. Technical success was achieved in all seven TAE procedures in six patients. Two patients with recurrent masses who had undergone hysterectomy presented with hematochezia, and TAE was able to provide technical success in these patients as well. The clinical success rate was 50%, indicating bleeding control for > 1 week. Rebleeding was directly associated with death in one patient. On the following day, mild fever was observed in one patient.

Conclusion: TAE can be considered an effective and safe method of bleeding control for uterine body cancer, especially during critical periods throughout the disease course of patients with inoperable, advanced-stage cancer.
Author(s)
자궁체부암 출혈에 대한 보존적 치료로써의 경카테터 동맥 색전술
Issued Date
2023
Jaeyeon Choi
Ji Hoon Shin
Hee Ho Chu
Type
Article
Keyword
EmbolizationTherapeuticEndometrial CancerUterine Artery EmbolizationUterine Neoplasms
DOI
10.3348/jksr.2022.0067
URI
https://oak.ulsan.ac.kr/handle/2021.oak/16183
Publisher
대한영상의학회지
Language
한국어
ISSN
1738-2637
Citation Volume
84
Citation Number
3
Citation Start Page
606
Citation End Page
614
Appears in Collections:
Medicine > Nursing
공개 및 라이선스
  • 공개 구분공개
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.